【ChiCTR1900025550】Concurrent Transcranial Direct Current Stimulation with Cognitive Training for Cognitive Functions of Schizophrenia Patients
ChiCTR1900025550
正在进行
/
/
/
2019-08-31
/
/
精神分裂症
Concurrent Transcranial Direct Current Stimulation with Cognitive Training for Cognitive Functions of Schizophrenia Patients
A Randomised Controlled Trial of Online Transcranial Direct Current Stimulation (tDCS) in Enhancing the Effects of Cognitive Training in patients with Schizophrenia
The primary objective of the study is to investigate the adjunct effect of online tDCS with cognitive training on specific cognitive domains in stable schizophrenia patients. (i) right after the intervention (ii) whether maintenance effect at 1 month after intervention. The secondary objective of the study is to probe (i) any effects on affective , psychotic and negative symptoms; (ii) psychosocial functioning, subjective quality of life (QOL); (iii) the motivation and enjoyment of continuing playing the computerized cognitive training; (iv) the tolerability and adverse events of tDCS among patients with schizophrenia.
随机平行对照
治疗新技术
The subjects will be randomly allocated to the intervention group or the control group by a block randomization procedure (1:1 allocation) . The randomization sequence will be generated by an online randomization tool (www.sealedenvelop.com) .
Double Blind
N/A
/
16
/
2019-08-01
2020-06-30
/
1. Patients receiving rehabilitation service in Tai Po Hospital aged between 18-65 years old; 2. diagnosis of schizophrenia meeting the diagnostic criteria of the World Health Organizations 10thversion of the International Statistical Classification of Disease and Related Health Problems (ICD-10),it will be made clinically by the study psychiatrist based on ICD-10; 3. right-handedness; 4. able to understand spoken instructions in Cantonese and able to read traditional Chinese.;
请登录查看1. History of significant head trauma; 2. active abuse of alcohol or illegal substances; 3. significant neurologic history such as dementia, stroke, seizure, Parkinsons disease, multiple sclerosis; 4. concurrent use of cognitive-enhancing medications e.g. acetylcholinesterase inhibitors ; 5. documented history of learning disability; f. implanted with pacemakers, intracranial electrodes, defibrillators; g. changes in medication regime over the 2 weeks before or during the study period.;
请登录查看香港中文大學大埔醫院
/
香港中文大學大埔醫院的其他临床试验
香港中文大學大埔醫院的其他临床试验
最新临床资讯
-
护肾先锋 | 逆转“不可逆”:88岁高龄“糖尿病肾病”患者,精准诊治重获新生
广东省中医院2026-08-14
-
破除临床痛点,医院原创冠脉微循环无创诊疗技术获全球权威认可
西南医院2026-08-14
-
bioSeedin柏思荟2026-08-14
-
迈同生物2026-08-14
-
COD医材汇2026-08-14
-
九源基因2026-08-14
-
丁香园 Insight 数据库2026-08-14
-
辐联科技Full Life Technologies2026-08-14
-
茵诺医药2026-08-14
-
优赛生命2026-08-14
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-08-15
-
2026-08-15
-
2026-08-15
-
摩熵咨询 20 8
-
摩熵咨询 34 29
-
摩熵咨询 20 5
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构:国家医保局 2026-07-31
-
颁布机构:国家药品审评中心(CDE) 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-08-15
-
2026-08-14
-
2026-08-14
-
摩熵咨询 35 37
-
摩熵咨询 28 39
-
摩熵咨询 34 19
-
颁布机构:国家市场监督管理总局 2026-08-10
-
颁布机构:国家市场监督管理总局 2026-05-29
-
颁布机构:国家市场监督管理总局 2026-05-29
